Request Trial
voodoo13-shutterstock-com
VooDoo13 / Shutterstock.com
4 August 2016AmericasMark Remus

IPR: five tips for successfully challenging Orange Book patents

Inter partes review (IPR) provides an attractive alternative to district court litigation. The Patent Trial and Appeal Board (PTAB) applies a lower burden of proof and reaches a decision more quickly and cheaply than district courts. Generic pharmaceutical companies can use these advantages to get their products to market faster and more cost-effectively. The following are five tips for a successful IPR challenge.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US biotech fires trade secrets suit at Chinese pharma group
10 June 2026   Valuable antibody technology, a former employee, and a dispute over patent rights extending across the US, Europe and Asia at the heart of the latest suit.
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026   A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.
Americas
Fed Circ rejects Nexus’ appeal in generics row with biopharma firm
8 June 2026   Nexus Pharmaceuticals is knocked back by the US Court of Appeals, which upholds a district court finding that it infringed a rival’s patents.


Editor's picks

Hikma v Amarin: Six takeaways from the pivotal ruling
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

Editor's picks

Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI
14 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Americas
Penile implant maker’s $17m trade secret award unravels
20 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026

More features

US biotech fires trade secrets suit at Chinese pharma group
Hikma v Amarin: Six takeaways from the pivotal ruling
Fed Circ rejects Nexus’ appeal in generics row with biopharma firm
Hikma triumphs at SCOTUS in landmark skinny-label ruling
Pfizer strikes $10.5 billion oncology deal with Chinese biotech
Dehns appoints head of litigation following wave of senior hires
Chadha & Chadha hires former Remfry & Sagar patent partner
Heated LNP litigation puts Moderna and Acuitas in the spotlight